Novoheart (TSX VENTURE:NVH) (FRANKFURT:3NH) Opens New State-Of-The-Art Facilities at the Hong Kong Science Park
- Brand new 5,300 ft² integrated laboratory and office space, fully equipped for scalable stem cell production and tissue engineering
- Expanded capacity able to accommodate significantly increased number of commercial contracts and partner projects
- Strategically located to take advantage of rapidly growing Asian market
- Eligible to benefit from local government R&D subsidies for development of new technologies for global commercialization
- Streamlined coordination with Company's US laboratory, driving complimentary R&D innovation
VANCOUVER, BRITISH COLUMBIA - March 14, 2018 (Investorideas.com Newswire) Novoheart ("Novoheart" or the "Company") (TSX VENTURE:NVH)(FRANKFURT:3NH) is pleased to announce the opening of its brand new Hong Kong facility consisting of 5,300 ft² of integrated laboratory and office space. Located in the Hong Kong Science Park, the laboratory is equipped with state-of-the-art facilities for stem cell production, tissue engineering and world-class research and development. The facility provides Novoheart with a new level of scalability enabling it to accommodate a significant number of additional revenue-generating commercial contracts and projects.
"Our new, state-of-the-art facility and Hong Kong location allows us to now take full advantage of the booming Asian market and build regional strategic partnerships while also accommodating an increased number of revenue-generating opportunities within North America," said Dr. Ronald Li, CEO of Novoheart. "Our location also allows us access to local government funding to support new and pioneering R&D activities. In the past few years, Novoheart has secured approximately $2 million in government support which has allowed us to accelerate the development of our market-leading technologies for commercialization."
"With the newly expanded Hong Kong facilities, operations are being streamlined to ensure its growing R&D team works seamlessly with those located in our Irvine, California location, and the two locations enable our R&D programs to operate continuously round the clock." said Dr. Kevin Costa, CSO of Novoheart. "In addition to this facility being an advantage for our global client-base, we believe we will rapidly accelerate our ability to innovate in key areas of research and ensure we continue to deliver best-in-class drug discovery tools for our pharmaceutical and biotech clients."
Novoheart is a global stem cell biotechnology company pioneering an array of next-generation human heart tissue prototypes. It is the first company in the world to have engineered miniature living human heart pumps that can revolutionize drug discovery, helping to save time and money for developing new therapeutics. Also known as 'human heart-in-a-jar', Novoheart's bio-artificial human heart constructs are created using state-of-the-art and proprietary stem cell and bioengineering approaches and are utilized by drug developers for accurate preclinical testing as to the effectiveness and safety of new drugs, maximizing the successes in drug discovery whilst minimizing costs and harm caused to patients.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
Information set forth in this news release may involve forward-looking statements under applicable securities laws. Forward-looking statements are statements that relate to future, not past, events. In this context, forward-looking statements often address expected future business and financial performance, and often contain words such as "anticipate", "believe", "plan", "estimate", "expect", and "intend", statements that an action or event "may", "might", "could", "should", or "will" be taken or occur, or other similar expressions. All statements, other than statements of historical fact, included herein including, without limitation; statements about the Company's future plans, its goals and expectations, and the potential applications of its MyHeart™ platform are forward-looking statements. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the risks identified in the management discussion and analysis section of Novoheart Holdings Inc.'s interim and most recent annual financial statement or other reports and filings with the TSX Venture Exchange and applicable Canadian securities regulators. Forward-looking statements are made based on management's beliefs, estimates and opinions on the date that statements are made and the respective companies undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable securities laws. Investors are cautioned against attributing undue certainty to forward-looking statements.
Virtus Advisory Group
For media enquiries or interviews, please contact:
This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release on the Investorideas.com newswire https://www.investorideas.com/News-Upload/
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: https://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.